The last decade has seen a “dramatic increase” in investigational new drug (IND) applications for cannabis-derived products, according to the U.S. Food and Drug Administration.
Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50
A two-day event hosted by the Food and Drug Law Institute highlighted cannabis regulatory headaches, including delta-8 THC and a lack of uniformity in lab testing.